Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
20 participants
INTERVENTIONAL
1998-07-31
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TCV -01-002: T-Cell Vaccination in the Treatment of Probable Multiple Sclerosis
NCT00228228
T Cell Vaccination in Patients With Progressive Multiple Sclerosis
NCT01448252
Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis
NCT00587691
Efficacy of Anti-Tubercular Vaccination in Multiple Sclerosis
NCT00202410
A "negative"dendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial
NCT02618902
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Clinical immunologic and neuroradiologic evaluation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
ECT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
T-Cell Vaccination
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Relapsing remitting or primary progressive clinical course. At least one relapse in the last two years.
* Disease duration \> 1 year
* Expanded Disability Status Scale (EDSS) between 0-6
* Brain magnetic resonance imaging (MRI) compatible with MS
* Not involved in any other clinical trials
* No other systemic disease
Exclusion Criteria
16 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sheba Medical Center
OTHER_GOV
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anat Achiron, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Sackler School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Multiple Sclerosis Center
Ramat Gan, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Matilda Mandel, MD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Matilda Mandel, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHEBA-98-1754-AA-CTIL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.